Related Experiment Video
Updated: May 20, 2026

Production and Visualization of Bacterial Spheroplasts and Protoplasts to Characterize Antimicrobial Peptide Localization
Published on: August 11, 2018
Antimicrobial peptides for bacterial infections and their biomedical applications
Zhiyang Gu1, Xiaotong Chen1, Chuqiang Yin1
1Department of Spine Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266003, People's Republic of China.
None:
Due to the rapid development of multidrug-resistant (MDR) bacteria due to the inappropriate use and misuse of antibiotics and the ineffective performance of antibiotics against refractory biofilm-associated infections (BRI), there is an urgent need for novel alternative antimicrobials and strategies to combat bacterial infections. Antimicrobial peptides (AMPs) have attracted considerable interest due to their potent activity against MDR pathogens and biofilm-associated infections, coupled with a substantially reduced risk of driving antimicrobial resistance-especially when employed as alternatives or adjuncts to conventional antibiotics. With the development of nanocarrier-based delivery strategies, AMP nanomaterials significantly improve the therapeutic effect of AMP by improving the hydrolytic stability, in vivo half-life, solubility, and reducing cytotoxicity and hemolysis of AMP. Distinct from previous reviews that primarily focus on AMP sequence engineering or generic nanocarrier types, this work adopts a clinically oriented framework organized by infection site-including pulmonary, bloodstream, gastrointestinal, chronic wound, and implant-associated infections. Key therapeutic outcomes reported in the literature are systematically compared, such as reductions in minimum inhibitory concentration (MIC), biofilm eradication efficiency, survival benefits in sepsis models, and wound closure kinetics. Formulation design strategies, administration routes, and the rational application of nanocarriers constructed from metallic elements, biocompatible polymers, and lipid-based architectures are discussed in the context of specific infectious microenvironments. By correlating the physicochemical properties of nanocarriers-such as surface charge, degradation profile, and release kinetics-with therapeutic performance across diverse infection models, this review also addresses the current limitations of AMP-based formulations in clinical applications. Overall, this review provides insights into the advantages and disadvantages of AMP-based nanomaterials currently under development for the treatment of bacterial infections in the literature, bringing inspiration and recommendations for their future design.
Related Concept Videos
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Biological Methods for Microbial Control
Inhibitors of Gram-positive Cell Wall Synthesis
Clinical Significance of Antibiotic Resistance
Gene Regulation in Microbial Communities: Quorum Sensing
Bacterial Signaling